Yu Mengting, Yan Duan, Wu Wenjie, Wang Yingbin, Wu Xinna
Ophthalmology Department, Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350001, China.
Ophthalmology Department, Fujian Provincial Hospital, Fuzhou 350001, China.
J Ophthalmol. 2020 Jul 30;2020:6287274. doi: 10.1155/2020/6287274. eCollection 2020.
To evaluate the safety and outcomes of primary posterior continuous curvilinear capsulorhexis (PPCCC) combined with phacoemulsification in postvitrectomy eyes.
Retrospective case series.
Twenty-one postvitrectomy eyes of 21 patients with cataract between April 2017 and December 2019 were enrolled. PPCCC through the cornea incision was performed before in-the-bag intraocular lens implantation. All patients were followed up for at least 3 months postoperatively. The outcome measures were corrected distance visual acuity (CDVA), intraocular pressure (IOP), corneal endothelium cell counts (CECC), central macular thickness (CMT), the occurrence of intraoperative or postoperative complications, and the incidence of posterior capsular opacification (PCO).
The mean age was 56.14 ± 9.76 years (ranging from 31 to 68). The mean Snellen CDVA was 20/400 preoperatively and improved to 20/67 postoperatively ( < 0.001). No significant differences were found between IOP ( = 0.96) and CMT ( = 0.42) preoperatively and postoperatively. The mean CECC was 2571.8 ± 319.3 cells/mm preoperatively and 2498.2 ± 346.3 cells/mm postoperatively ( < 0.05). Lens epithelium cells proliferation was confined to the peripheral capsular bag during a mean follow-up of 12.9 ± 10.5 months (ranging from 3 to 28 months). Intraoperative posterior capsule extension occurred in 1 eye (4%), although it did not affect the patient's vision. No serious complications, including retinal detachment or endophthalmitis, were detected in any of the 21 cases.
PPCCC through cornea incision combined with phacoemulsification may be a safe and practical alternative to prevent PCO in postvitrectomy eyes with cataract.
评估原发性后连续环形撕囊术（PPCCC）联合超声乳化术在玻璃体切除术后眼中的安全性及疗效。
回顾性病例系列研究。
纳入2017年4月至2019年12月期间21例患有白内障的患者的21只玻璃体切除术后眼。在行囊内人工晶状体植入术前，通过角膜切口进行PPCCC。所有患者术后至少随访3个月。观察指标包括矫正远视力（CDVA）、眼压（IOP）、角膜内皮细胞计数（CECC）、黄斑中心厚度（CMT）、术中或术后并发症的发生情况以及后囊膜混浊（PCO）的发生率。
平均年龄为56.14±9.76岁（范围为31至68岁）。术前平均Snellen CDVA为20/400，术后提高至20/67（P<0.001）。术前和术后IOP（P = 0.96）和CMT（P = 0.42）之间未发现显著差异。术前平均CECC为2571.8±319.3个细胞/mm²，术后为2498.2±346.3个细胞/mm²（P<0.05）。在平均12.9±10.5个月（范围为3至28个月）的随访期间，晶状体上皮细胞增殖局限于周边囊袋。1只眼（4%）术中出现后囊膜伸展，尽管未影响患者视力。21例患者中均未检测到包括视网膜脱离或眼内炎在内的严重并发症。
通过角膜切口的PPCCC联合超声乳化术可能是预防玻璃体切除术后白内障眼中PCO的一种安全且实用的方法。
